Pharmos
Corporation to Present at Friedland Capital's
Biotech, Medical and Healthcare Conference
Featuring Companies Covered by J. M. Dutton & Associates
Iselin
NJ, September 23, 2003 - Pharmos Corporation's (Nasdaq:
PARS - News) Executive VP & Chief Financial Officer,
Robert W. Cook, will present at 12:20 pm Eastern Time
on September 24th at Friedland Capital's Biotech, Medical
and Healthcare Conference, featuring companies covered
by the research firm J. M. Dutton & Associates, at
the Harvard Club in New York City. Mr. Cook will present
Pharmos' corporate message to key members of the investment
community including portfolio managers, analysts, brokers
and investment bankers. The presentation will be webcast
live at http://www.friedlandcapitalevents.com/duttonwebcast.htm
and will be available for replay in an archived version
at the same location for 60 days.
About
Pharmos Corporation
Pharmos discovers, develops, and commercializes
novel therapeutics to treat a range of indications, in
particular neurological and inflammation-based disorders.
The Company's first neuroprotective product is dexanabinol,
a tricyclic dextrocannabinoid, currently undergoing clinical
testing as a treatment for traumatic brain injury and
as a preventive agent against post-surgical cognitive
impairment. Other dextrocannabinoid compounds and CB2
receptor agonist compounds from Pharmos' proprietary synthetic
cannabinoid library are being studied in pre-clinical
programs targeting a variety of other disorders. For more
information on Pharmos, please visit www.pharmoscorp.com.
About Friedland Capital
Friedland Capital has been in business since
1979. The US based corporate finance advisory firm and
its principals have assisted emerging growth companies
worldwide in enhancing shareholder value and achieving
their US corporate finance objectives. Friedland Capital
is also the world's largest sponsor of financial community
and investment events, sponsoring over 150 conferences
and luncheons annually in 18 US cities and three European
cities, and bringing together publicly-traded global companies
with the financial community in a variety of industry
sectors. Friedland Capital events provide companies a
platform to showcase their management teams, company strategy
and business plans. Friedland Capital has offices in New
York, New Jersey, Chicago and Denver. For more information
regarding Friedland Capital, please visit www.friedlandcapitalevents.com.
About JM Dutton & Associates
J.M. Dutton & Associates is an investment research
firm that offers high-quality, independent, fundamental
research primarily on small-cap companies. These companies
are principally U.S.-traded companies, including issuers
of ADRs, and are based in North America, the United Kingdom,
Israel, and other EU countries. J.M. Dutton research reports
and notes are available on the worldwide institutional
systems of Bloomberg Professional System and First Call.
Zacks, Multex, and many others also carry their reports
and notes. All the major consensus estimates -- First
Call, Zacks, Multex, and the JCF
GROUP in Europe -- include the JM Dutton & Associates
estimates and stock
rating.
Statements made in this press release
related to the business outlook and future financial performance
of the Company, to the prospective market penetration
of its drug products, to the development and commercialization
of the Company's pipeline products and to the Company's
expectations in connection with any future event, condition,
performance or other matter, are forward-looking and are
made pursuant to the safe harbor provisions of the Securities
Litigation Reform Act of 1995. Such statements involve
risks and uncertainties which may cause results to differ
materially from those set forth in these statements. Additional
economic, competitive, governmental, technological, marketing
and other factors identified in Pharmos' filings with
the Securities and Exchange Commission could affect such
results.
back
to News Room
